Vol. 2 No. 10 (2022)
Reimbursement Recommendations

Selpercatinib (Retevmo)

Published October 13, 2022

Key Messages

  • CADTH recommends that Retevmo should be reimbursed by public drug plans for the treatment of rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) patients 12 years of age and older with advanced or metastatic disease if certain conditions are met.
  • Retevmo should only be covered to treat patients whose disease has progressed while taking a first-line treatment, and for those who cannot tolerate or have a contraindication to first-line therapies.
  • Retevmo should only be reimbursed if prescribed by clinicians with experience in the management of patients with thyroid cancer, it is not given in combination with other anticancer drugs, and the price of Retevmo is reduced.